Peregrine Pharma New (PPHM) 0.42 $PPHM Peregrine

New Post Public Reply Private Reply Replies (0) Message Board

Apr 1, 2016 at 3:44 AM

Peregrine Pharma New (PPHM) 0.42 $PPHM

Peregrine Pharmaceuticals Reports Financial Results for Third Quarter of Fiscal Year 2016 and Recent Developments
GlobeNewswire - Wed Mar 09, 7:22AM CST
--Company Focused on Advancing Its Bavituximab Immuno-Oncology Program Through Its Pharmaceutical, Academic and Clinical Collaborations--
PPHMP: 17.80 (+0.05), PPHM: 0.42 (+0.02)

Peregrine reports 3Q loss
Automated Insights - Wed Mar 09, 7:13AM CST
TUSTIN, Calif. (AP) _ Peregrine Pharmaceuticals Inc. (PPHM) on Wednesday reported a loss of $16.8 million in its fiscal third quarter.
PPHM: 0.42 (+0.02)

Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
GlobeNewswire - Mon Mar 07, 3:05PM CST
Peregrine Pharmaceuticals, Inc. (Nasdaq

PHM) (Nasdaq

PHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"

.
PPHMP: 17.80 (+0.05), PPHM: 0.42 (+0.02)

Peregrine Pharmaceuticals Announces Formal Commissioning of New, State-of-the-Art Commercial Manufacturing Facility
GlobeNewswire - Mon Mar 07, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ

PHM) (NASDAQ

PHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that its new state-of-the-art commercial biomanufacturing suite in Tustin, California, has been formally commissioned. As part of the commissioning process, all relevant regulatory agencies have been notified and cGMP production is currently underway. The new Peregrine facility, which is being operated by Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine, will more than double the company's prior manufacturing capacity, supporting up to an additional $40 million in revenue each year.
PPHMP: 17.80 (+0.05), PPHM: 0.42 (+0.02)

Peregrine to Report Financial Results for Third Quarter of Fiscal Year 2016 Prior to Market Open on March 9, 2016
GlobeNewswire - Thu Mar 03, 3:05PM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ

PHM) (NASDAQ

PHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it will report financial results for the third quarter of fiscal year 2016 ended January 31, 2016 on March 9, 2016 prior to market open and will host a conference call and webcast at 8:30 AM Pacific Time (11:30 AM Eastern Time). Peregrine's senior management will discuss financial results for the third quarter and review the recent progress of its clinical development programs.
PPHMP: 17.80 (+0.05), PPHM: 0.42 (+0.02)

OncBioMune Patents a New Promising Approach to Chemotherapy
ACCESSWIRE - Thu Jan 28, 7:00AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 28, 2016 / Chemotherapy compounds like paclitaxel and docetaxel have been used for years to treat cancer, but the caveat is that they indiscriminately kill both cancerous and normal cells. In order to solve this problem, researchers have tried a number of different approaches. The most common approach has been conjugating anti-cancer agents to antibodies or functional fragments, but even then, there are significant numbers of normal cells affected.
SGEN: 35.09 (+1.45), IMGN: 8.52 (+0.26), PPHM: 0.42 (+0.02), SRNE: 5.38 (+0.15), CELG: 100.09 (+1.29)

Peregrine Pharma (PPHM): Strong Industry, Solid Earnings Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Fri Jan 22, 7:43AM CST
Peregrine Pharma is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
PPHM: 0.42 (+0.02)

Peregrine Pharmaceuticals to Present at Two Upcoming Cancer Immunotherapy Conferences
GlobeNewswire - Wed Jan 20, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ

PHM) (NASDAQ

PHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that members of the company's scientific team will deliver podium presentations focused on the role of combination immunotherapies in the treatment of cancer at two upcoming immunotherapy conferences. Jeff T. Hutchins, Ph.D., Peregrine's vice president, preclinical research, will speak at Immunotherapy World 2016, being held January 25-27, 2016 in Washington, D.C. Additionally, Bruce Freimark, Ph.D., research director, preclinical oncology at Peregrine, will present at GTCBio's 8th Immunotherapeutics & Immunomonitoring Conference, being held January 25-26, 2016 in San Diego, CA.
PPHMP: 17.80 (+0.05), PPHM: 0.42 (+0.02)

Peregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab Clinical Program in Lung, Breast and Other Cancers
GlobeNewswire - Mon Jan 11, 7:05AM CST
-- Phase II Study in NSCLC in Collaboration with AstraZeneca Evaluating Bavituximab Plus Durvalumab to Expand Lung Cancer Program in Q1 2016 --
PPHMP: 17.80 (+0.05), PPHM: 0.42 (+0.02)

Peregrine (PPHM) Inks Research Partnership for Bavituximab
Zacks Equity Research - Zacks Investment Research - Thu Jan 07, 1:00PM CST
Peregrine (PPHM) is collaborating with the National Comprehensive Cancer Network to evaluate bavituximab for the treatment of a range of tumors.
AZN: 28.16 (-0.16), HZNP: 16.57 (+0.56), PPHM: 0.42 (+0.02), SNY: 40.16 (-0.53)

Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With Bavituximab
GlobeNewswire - Wed Jan 06, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ

PHM) (NASDAQ

PHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced a new research collaboration with the National Comprehensive Cancer Network(R) (NCCN(R)) to expand the company's ongoing clinical research and development of bavituximab for the treatment of a range of tumors. NCCN, a not-for-profit alliance of 26 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Peregrine will fund multiple investigator-initiated clinical and correlative studies with bavituximab in multiple cancers at NCCN Member Institutions and their affiliate community hospitals through a $2 million research grant to NCCN's Oncology Research Program (ORP). NCCN will be responsible for oversight and monitoring of the clinical studies through the research grant.
PPHMP: 17.80 (+0.05), PPHM: 0.42 (+0.02)

Surging Earnings Estimates Signal Good News for Peregrine Pharmaceuticals (PPHM)
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 7:46AM CST
Peregrine Pharmaceuticals has decent short-term momentum and is also seeing solid activity on the earnings estimate revision front as well.
PPHM: 0.42 (+0.02)

The Life Sciences Report Announces 19 Companies for the 2016 Small-Cap Biotech Watchlist
Marketwired - Tue Dec 22, 8:01AM CST
In advance of the Biotech Showcase 2016, The Life Sciences Report has once again solicited top analysts to provide the names of innovative biotech companies that investors should keep an eye on in the upcoming year.
CRMD: 2.65 (+0.22), PIRS: 1.90 (unch), AST: 4.70 (+0.01), PPHM: 0.42 (+0.02)

Why You Shouldn't Bet Against Peregrine Pharmaceuticals (PPHM) Stock
Zacks Equity Research - Zacks Investment Research - Tue Dec 22, 7:39AM CST
Peregrine Pharmaceuticals (PPHM) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
PPHM: 0.42 (+0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovent's SINTBILO® Hits Primary Endpoint in Study

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

TCL Tablets Arrive on BestBuy.com: What It Means

Go Big or Go Home: TCL's Bold Move TCL just dropped a little bombshell that's gonna ripple through the electronics retail market—its tablets and smartphones are now bright and shiny on BestBuy.com. It's like standing at the craps table and before you know it, the stakes have just doubled. Why? Best Buy ain't some hole-in-the-wall spot. It's the premium electronics...

ASTS Faces Class Action; Investors Beware of Pitfalls

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Formation Unveils First Solana Tokenized Securities Venue

Well, here we go. Formation Securities is setting sail on the high seas of blockchain, aiming to operate a tokenized securities venue (TSV) on Solana. This isn't your garden-variety launch—it's a bold leap into a newer, faster-paced world of trading. Sure, you’ve heard about blockchains before, but this operation marries the traditional rigmarole of the stock market...

Continuous Insulation Market Grows, Hits $67.74B by 2031

Market Trends and Key Drivers Imagine riding a slow but steady bull market in insulation—sounds mundane, but the numbers don't lie. MarketsandMarkets™ had the scoop, predicting the Continuous Insulation Market will balloon from USD 56.98 billion in 2026 to USD 67.74 billion by 2031, putting down roots with a 3.5% CAGR. Now, you and I both know that when real estate...

Tigo Energy Faces Class Action: Investor Deadline Looms

Unpacking Tigo's Rollercoaster: Lawsuit & Market Reaction They sometimes say, "When it rains, it pours." For Tigo Energy, it’s been more a downpour than a drizzle. Here we are, chasing down what's going on with Tigo Energy (NASDAQ:TYGO), fresh off the heels of a class action fuss that's grabbed every investor's attention. If you've got a stake, or even a passing...

O-I Glass Faces Class Action: Investor Implications

O-I Glass in Hot Water Over Misleading Statements I'll tell you, nothing gets my goat quite like uncovering deceptive practices in the corporate world. It seems O-I Glass, Inc. (NYSE: OI), might have played a fast one with its shareholders. The company is staring down the barrel of a class action lawsuit from Schall, Brown & Schwartz LLP, alleging they weren't entirely...

Photocure Navigates AssureMDx's Medicare Journey

Aiming High with AssureMDx Photocure's got this bladder cancer test called AssureMDx that's at the center of its recent moves after acquiring Vesica Health a few months back. This isn't just any test; it's a urine-based, non-invasive way to snag an early look at bladder cancer. With the FDA's Breakthrough Device tag pinned on, they're not just dipping their toes in—this...

AWS Boosts Agilix's AI Education in Sierra Leone

Agilix Labs' Landmark Leap with AWS Just when you think you've got the grip on global education dynamics, a new wave hits your shores, this time courtesy of Agilix Labs and AWS. Agilix Labs snagged a grant from Amazon Web Services, carving a path that blends AI with educational equity in Sierra Leone. Now, if that doesn’t prick up investor ears or yank a few...

Zabalafin Hydrogel: Promise in Treating Atopic Dermatitis

Pioneering a New Path in Dermatology Treatment In the world of dermatology, finding a topical solution that tackles the full spectrum of atopic dermatitis (AD) is as rare as hens' teeth. But here's a twist—in a recent research paper gracing the Journal of Drugs in Dermatology, Alphyn Biologics sheds light on their unique contender, Zabalafin Hydrogel. This ain't your...